2269:HKG
WuXi Biologics (Cayman) Inc
48,20 HKD
arrow_downward
-0,90%(-0,44) 1 d
16 oct, 16:08:14 GMT+8 · HKD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de 2269...
Abrir
49,98 HKD
Alto
50,85 HKD
Bajo
45,82 HKD
Cap. burs.
198,43 mil M
Vol. medio
30,42 M
Volumen
55,18 M
Ratio PER
34,48
Máximo en 52 sem.
58,00 HKD
Mínimo en 52 sem.
28,48 HKD
BPA
1,40 HKD
Acciones en circulación
1225,23 M
N.º de empleados
15 mil
Abrir
49,98 HKD
Alto
50,85 HKD
Bajo
45,82 HKD
Cap. burs.
198,43 mil M
Vol. medio
30,42 M
Volumen
55,18 M
Ratio PER
34,48
Máximo en 52 sem.
58,00 HKD
Mínimo en 52 sem.
28,48 HKD
BPA
1,40 HKD
Acciones en circulación
1225,23 M
N.º de empleados
15 mil
Noticias
De fuentes web y partners de noticias
es.qz.com
·
hace 13 horas
El Nasdaq cae un 2% mientras continúa la venta de acciones de chips e inteligencia artificial el viernes.
XTB.com
·
hace 13 horas
Resultados en Wall Street: ganadores y perdedores del S&P 500
El Ecosistema Startup
·
hace 11 horas
S&P 500 sube a 7.744 con rotación fuera de la IA
TradingView
·
hace 20 horas
Futuros del Dow suben 145 puntos: 5 claves antes de la apertura de Wall Street el 16 oct.
Perfil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Acerca de WuXi Biologics (Cayman) Inc